Sökning: WFRF:(Halvorsen Matthew W) >
Percutaneous corona...
Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin : Insights from the ARISTOTLE trial
-
- Kopin, David (författare)
- Duke University School of Medicine, Durham, USA
-
- Jones, W Schuyler (författare)
- Duke University School of Medicine, Durham, USA
-
- Sherwood, Matthew W (författare)
- Inova Heart and Vascular Institute, Fairfax, USA
-
visa fler...
-
Wojdyla, Daniel M (författare)
-
- Wallentin, Lars, 1943- (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),UCR
-
- Lewis, Basil S (författare)
- The Ruth and Bruce Rappaport School of Medicine of the Technion, Haifa, Israel
-
- Verheugt, Freek W A (författare)
- Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands
-
- Vinereanu, Dragos (författare)
- University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital of Bucharest, Bucharest, Romania
-
- Bahit, M Cecilia (författare)
- INECO Neurociencias Oroño, Rosario, Argentina
-
- Halvorsen, Sigrun (författare)
- University of Oslo, Oslo, Norway
-
- Huber, Kurt (författare)
- Hospital and Sigmund Freud Private University, Medical School, Vienna, Austria
-
- Parkhomenko, Alexander (författare)
- Institute of Cardiology, Kiev, Ukraine
-
Granger, Christopher B (författare)
-
Lopes, Renato D (författare)
-
Alexander, John H (författare)
-
visa färre...
-
(creator_code:org_t)
- New York : Elsevier BV, 2018
- 2018
- Engelska.
-
Ingår i: American Heart Journal. - New York : Elsevier BV. - 0002-8703 .- 1097-6744. ; 197, s. 133-141
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: We assessed antiplatelet therapy use and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ARISTOTLE trial.METHODS: Patients were categorized based on the occurrence of PCI during follow-up (median 1.8 years); PCI details and outcomes post-PCI are reported. Of the 18,201 trial participants, 316 (1.7%) underwent PCI (152 in apixaban group, 164 in warfarin group).RESULTS: inhibitor; 32% received antiplatelet agents without OAC. Post-PCI, patients assigned to apixaban versus warfarin had numerically similar rates of major bleeding (5.93 vs 6.73 events/100 patient-years; P = .95) and stroke (2.74 vs 1.84 events/100 patient-years; P = .62).CONCLUSIONS: PCI occurred infrequently during follow-up. Most patients on study drug at the time of PCI remained on study drug in the peri-PCI period; 19% continued the study drug without interruption. Antiplatelet therapy use post-PCI was variable, although most patients received DAPT. Additional data are needed to guide the use of antithrombotics in patients undergoing PCI.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kopin, David
-
Jones, W Schuyle ...
-
Sherwood, Matthe ...
-
Wojdyla, Daniel ...
-
Wallentin, Lars, ...
-
Lewis, Basil S
-
visa fler...
-
Verheugt, Freek ...
-
Vinereanu, Drago ...
-
Bahit, M Cecilia
-
Halvorsen, Sigru ...
-
Huber, Kurt
-
Parkhomenko, Ale ...
-
Granger, Christo ...
-
Lopes, Renato D
-
Alexander, John ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
American Heart J ...
- Av lärosätet
-
Uppsala universitet